Drugs / SYN125
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04363242 | Apr 2020 → Jul 2023 | carcinoma | Synermore Biologics Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYN125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04363242 ↗ |
| Route | Intravenous | “Administered by IV infusion” NCT04363242 ↗ |